Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax: 2021-2025

Historic Long-Term Deferred Tax for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Sep 2025 value amounting to $101.7 million.

  • Ironwood Pharmaceuticals' Long-Term Deferred Tax fell 45.13% to $101.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.7 million, marking a year-over-year decrease of 45.13%. This contributed to the annual value of $144.2 million for FY2024, which is 32.07% down from last year.
  • Ironwood Pharmaceuticals' Long-Term Deferred Tax amounted to $101.7 million in Q3 2025, which was down 21.45% from $129.5 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Long-Term Deferred Tax peaked at $337.8 million during Q2 2021, and registered a low of $101.7 million during Q3 2025.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Long-Term Deferred Tax value was $193.0 million (recorded in 2024), while the average stood at $189.6 million.
  • Data for Ironwood Pharmaceuticals' Long-Term Deferred Tax shows a maximum YoY tumbled of 45.13% (in 2025) over the last 5 years.
  • Ironwood Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $333.3 million in 2021, then dropped by 14.89% to $283.7 million in 2022, then fell by 25.15% to $212.3 million in 2023, then plummeted by 32.07% to $144.2 million in 2024, then slumped by 45.13% to $101.7 million in 2025.
  • Its last three reported values are $101.7 million in Q3 2025, $129.5 million for Q2 2025, and $143.6 million during Q1 2025.